Kopp Family Office, LLC
Long book
$145.3M
Q1 2026
Positions
21
Top-10 weight
92%
concentration
Last quarter
+11.7%
SPY +14.8%
Turnover
9%
of book per quarter
Strategy in plain words
auto-generated from filingsKopp Family Office, LLC is a wealth-management firm allocating client money, running a $145.3M US long book across 21 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. The book barely moves quarter to quarter — a patient, low-turnover holder. Current anchor positions: VANGUARD FTSE DEVELOPED ETF, ISHARES CORE U.S. AGGREGATE, INVESCO S&P 500 EQUAL WEIGHT, SS SPDR S&P 500 ETF TRUST-US, VANGUARD FTSE EMERGING MARKE.
Over the last 9 quarters its long book ran on average 3.8pp per quarter behind the S&P 500, beating the index in 2 of 9 quarters. Its holdings are mechanical (indexing / client flows), so position changes carry no stock-picking signal.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-9.8%
Q2 2024
+3.6%
Q3 2024
+5.8%
Q4 2024
-11.4%
Q1 2025
+4.1%
Q2 2025
+5.6%
Q3 2025
+5.0%
Q4 2025
-8.6%
Q1 2026
+11.7%
Sector allocation
Healthcare 43%
Technology 32%
Consumer discretionary 15%
Services media 10%
Long book by quarter
What does Kopp Family own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| VCEL VERICEL CORP | Healthcare | 163.4K | $5.3M | 3.6% | +1.1% |
| HWKN HAWKINS INC | Consumer discretionary | 27.0K | $4.1M | 2.8% | -1.2% |
| ATEC ALPHATEC HOLDINGS INC | Healthcare | 328.7K | $3.6M | 2.5% | Held |
| WK WORKIVA INC | Technology | 55.9K | $3.3M | 2.3% | Held |
| XMTR XOMETRY INC-A | Services media | 72.4K | $3.0M | 2.0% | -39.1% |
| TCMD TACTILE SYSTEMS TECHNOLOGY I | Healthcare | 85.0K | $2.2M | 1.5% | -33.2% |
| MANH MANHATTAN ASSOCIATES INC | Technology | 16.3K | $2.2M | 1.5% | Held |
| MSFT MICROSOFT CORP | Technology | 5.0K | $1.8M | 1.3% | -41.2% |
| NTNX NUTANIX INC - A | Technology | 43.4K | $1.7M | 1.1% | -50.6% |
| VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 55.3K | $1.1M | 0.7% | -68.1% |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | Apr 20, 2026 | 21 | $145.3M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Jan 12, 2026 | 21 | $156.7M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Oct 16, 2025 | 26 | $153.6M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Jul 15, 2025 | 27 | $154.5M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 14, 2025 | 28 | $144.7M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 13, 2025 | 21 | $157.8M | $K fixed canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Dec 31, 2024 | 22 | $157.0M | $K fixed canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Jul 29, 2024 | 21 | $161.2M | $K fixed canonical | SEC ↗ |
| Q1 2024 | 13F-HR | Jun 17, 2024 | 21 | $175.1M | $K fixed canonical | SEC ↗ |